[ad_1]
Toronto, Ontario–(Newsfile Corp. – April 4, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”); A company engaged in the production, cultivation, and sale of functional mushrooms and mushroom home-growing kits in North America and Europe, complying with all applicable laws, and selling a premium brand of psilocybin truffles for the legal recreational market in the Netherlands. is pleased to be able to announce this. A groundbreaking collaboration with Professor David Nutt and the respected organization Drug Science. The partnership aims to leverage data from Red Light Holland’s pioneering privacy-first microdosing app (https://imicroapp.com). The app collects anonymized data from users who agree to share their experiences microdosing with the company’s psilocybin truffles.
Under the guidance of Professor David Nutt, an internationally recognized expert in psychedelic neuropsychopharmacology, and in partnership with Drug Science, the UK’s leading independent scientific body on drugs, this collaboration will The purpose is to analyze the data to gain insight into usage and potential benefits. Microdosing of psilocybin. This initiative demonstrates how microdosing is safe and effective by focusing on data collected in the naturalistic and legal environment of the Netherlands, where our psilocybin truffles are sold responsibly. We aim to understand how it can be used.
Commenting on the partnership, Professor David Nutt said: “This partnership provides a unique opportunity to study psilocybin microdosing in a legal context, which will provide insight into its efficacy and potential therapeutic benefits. Data collected from Red Light Holland’s app will help guide future research, including the use of microdosing to treat mental health issues and policy development.”
The primary objective of this partnership is to inform and support the development of evidence-based regulations that promote responsible access to psilocybin microdosing. Red Light Holland’s commitment to privacy and ethical standards ensures that all shared data is anonymized and used for research purposes only, while respecting user privacy and security.
Todd Shapiro, CEO of Red Light Holland, said: “Our collaboration with Professor Nutt and Drug Discovery Sciences represents an important step forward in our mission to explore the therapeutic potential of psilocybin microdosing. ” he said. “By analyzing real-world data from Red Light from one of the world’s most respected experts in pharmaceutical research, we provide valuable insight into the ongoing debate about the potential benefits of microdosed psilocybin therapy. We want to provide and pave the way for responsible healthcare. Regulated access.”
About Red Light Holland
Red Light Holland is an Ontario-based company that produces, cultivates, and sells functional mushrooms and mushroom home-growing kits in North America and Europe, and has compliantly brought psilocybin to the legal recreational market in the Netherlands. We offer premium brands of truffles. together with all applicable laws.
Additional information about the company:
tod shapiro
Chief Executive Officer and Director
Phone number: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co
About drug discovery science
Drug Science Consultancy provides research advice and consulting services to corporations, governments and other stakeholders in all drug-related areas, with a particular focus on the emerging cannabis and psychedelic markets. We are the independent, commercially oriented trading arm of the Drug Science charity. All profits are returned to the charity to support its charitable causes.
For more information, please contact us below.
Email: Consultancy@drugscience.org.uk
Website: https://www.drugscience.org.uk/consultancy/
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. These statements relate to future events or our future performance. Words such as “may,” “intend,” “expect,” “believe,” “will,” “anticipate,” and “estimate” regarding matters that are not historical facts; Any use of similar expressions or descriptions is intended. Identifies forward-looking information and is based on the Company’s current beliefs or assumptions regarding the outcome and timing of such future events.
Forward-looking information and forward-looking statements contained herein include, without limitation, statements regarding: Our collaboration with Professor David Nutt and Pharmacology to analyze iMicroapp data and its impact on the understanding and regulation of psilocybin microdosing. Research possibilities from the data collected and the future of a hopeful regulatory environment for microdosing of psilocybin. Additionally, this collaboration aims to inform and support the development of responsible regulation and evidence-based therapeutic applications for psilocybin microdosing, including its potential benefits for mental health.
The forward-looking information in this press release is based on certain assumptions and expected future events. namely, Red Light Holland’s ability to collaborate effectively with Professor David Nutt and Pharmaceutical Sciences; The potential for iMicroapp data to provide meaningful insights into psilocybin microdosing. Ability to collaborate to influence policy development and therapeutic applications. Our commitment to privacy and ethical research standards in the collection and use of iMicroapp data.
These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those expressed or implied by such statements. This may be the cause. Potential regulatory changes impacting psilocybin research and microdosing. Microdosing of psilocybin for therapeutic purposes has become widely accepted socially.
Readers are cautioned not to read forward-looking statements because the assumptions used in the preparation of such information, although believed to be reasonable at the time of making, may prove to be incorrect. Please note that you should not rely on it too much. Forward-looking statements include, but are not limited to: Our future collaboration with Professor Nutt and Pharmaceutical Sciences. Possible insights and impacts from analyzing iMicroapp data. Such analysis could then contribute to the evidence base needed to develop responsible psilocybin microdosing regulations and understand its therapeutic efficacy.
Additionally, readers are cautioned not to place undue reliance on forward-looking statements. There can be no assurance that plans, intentions or expectations based on such statements will materialize. Although such information is considered reasonable by management at the time of preparation, it may prove to be incorrect and actual results may differ materially from those anticipated. .
The forward-looking statements contained in this press release, which are expressly qualified by this cautionary statement, reflect our expectations as of the date of this press release and are subject to change thereafter. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or as a result of subsequent actual events or the like. We do not undertake any obligation to explain material differences between forecasts. Information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/204280.
[ad_2]
Source link
